L-NAME hydrochloride
Based on 79 publication(s) in Google Scholar
L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM. L-NAME hydrochloride requires hydrolysis of the methyl ester by cellular esterases to become a fully functional inhibitor. L-NAME hydrochloride can be used to induce hypertension and preeclampsia models.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 51298-62-5
- Formula: C7H16ClN5O4
- Molecular Weight:269.69
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Neuroprotective Compound Library
HY-L070
-
Angiogenesis-Related Compound Library
HY-L088
-
Animal Disease Model Inducer Library
HY-L097
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Non-natural Amino Acid Compound Library
HY-L198
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) L-NAME hydrochloride
More- Signal Transduct Target Ther. 2025 May 28;10(1):167. [Abstract]
- Cancer Res. 2024 Jun 14;84(12):1963-1977. [Abstract]
- J Extracell Vesicles. 2023 May;12(5):e12328. [Abstract]
- Adv Sci (Weinh). 2026 May;13(25):e15367. [Abstract]
- Adv Sci (Weinh). 2024 Jun;11(21):e2309002. [Abstract]
- J Nanobiotechnology. 2025 Aug 26;23(1):590. [Abstract]
- Hum Reprod Open. 2026 Feb 17;2026(2):hoag013. [Abstract]
- Cardiovasc Diabetol. 2024 May 9;23(1):164. [Abstract]
- Cell Commun Signal. 2021 Mar 18;19(1):35. [Abstract]
- Phytomedicine. 2022 Sep:104:154242. [Abstract]
- Free Radic Biol Med. 2025 Apr 12:S0891-5849(25)00225-4. [Abstract]
- Free Radic Biol Med. 2024 Sep 13:S0891-5849(24)00659-2. [Abstract]
- Biomed Pharmacother. 2020 Jul:127:110121. [Abstract]
- Biomed Pharmacother. 2023 May:161:114484. [Abstract]
- Biomed Pharmacother. 2020 Aug;128:110240. [Abstract]
- Biomed Pharmacother. 2019 Jul:115:108934. [Abstract]
- Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1705-1721. [Abstract]
- Aging Cell. 2025 Sep 29:e70222. [Abstract]
- Aging Cell. 2025 Feb 6:e14502. [Abstract]
- JCI Insight. 2021 Sep 22;6(18):e133690. [Abstract]
- Int J Mol Med. 2024 Aug;54(2):67. [Abstract]
- Chem Biol Interact. 2025 May 28:111577. [Abstract]
- J Ethnopharmacol. 2022 Oct 5:296:115476. [Abstract]
- Cancer Metab. 2024 May 17;12(1):14. [Abstract]
- Commun Biol. 2025 Nov 25;8(1):1682. [Abstract]
- Nutrients. 2022 Nov 25;14(23):5025. [Abstract]
- Biol Direct. 2024 Nov 26;19(1):121. [Abstract]
- Int J Mol Sci. 2023 Mar 7;24(6):5111. [Abstract]
- Int Immunopharmacol. 2025 Dec 24:170:116055. [Abstract]
- Am J Physiol Cell Physiol. 2025 Oct 30. [Abstract]
- Int Immunopharmacol. 2024 Nov 13;143(Pt 3):113617. [Abstract]
- Int Immunopharmacol. 2024 Jan 25:127:111313. [Abstract]
- Clin Epigenetics. 2025 Nov 19;17(1):195. [Abstract]
- J Mol Med (Berl). 2025 Dec 16;104(1):6. [Abstract]
- FASEB J. 2025 Jul 31;39(14):e70817. [Abstract]
- FASEB J. 2025 Jun 15;39(11):e70697. [Abstract]
- Microorganisms. 2024 Dec 2;12(12):2483. [Abstract]
- FASEB J. 2024 Jul 31;38(14):e23844. [Abstract]
- J Cell Mol Med. 2024 Apr;28(8):1-11. [Abstract]
- Bioengineered. 2022 Jan;13(1):1320-1334. [Abstract]
- Mediators Inflamm. 2020 Oct 24;2020:1649453. [Abstract]
- Mediators Inflamm. 2019 Oct 7;2019:6168340. [Abstract]
- Hum Gene Ther. 2023 Jan;34(1-2):42-55. [Abstract]
- Sci Rep. 2026 Apr 24;16(1):18995. [Abstract]
- Sci Rep. 2025 Oct 31;15(1):38208. [Abstract]
- Front Med. 2021 Apr 13:8:634882. [Abstract]
- Toxicol Appl Pharmacol. 2019 Mar 1:366:83-95. [Abstract]
- Bosn J Basic Med Sci. 2017 May 20;17(2):132-137. [Abstract]
- Int J Med Sci. 2025 Jan 21;22(4):920-932. [Abstract]
- Mol Cell Probes. 2023 Feb:67:101896. [Abstract]
- Peptides. 2024 Dec 5:183:171333. [Abstract]
- Cell Tissue Res. 2022 Apr;388(1):181-194. [Abstract]
- Front Cardiovasc Med. 2021 Apr 13:8:654254. [Abstract]
- Microvasc Res. 2023 Jul:148:104531. [Abstract]
- Vet Microbiol. 2022 Sep:272:109514. [Abstract]
- Int J Immunopathol Pharmacol. 2022 Jan-Dec:36:3946320221111117. [Abstract]
- Clin Exp Pharmacol Physiol. 2025 Nov;52(11):e70081. [Abstract]
- J Cardiovasc Transl Res. 2024 Dec;17(6):1415-1426. [Abstract]
- Placenta. 2022 Jan:117:95-108. [Abstract]
- Placenta. 2021 Mar:106:30-39. [Abstract]
- BMC Nephrol. 2024 Jul 15;25(1):226. [Abstract]
- PeerJ. 2023 May 25:11:e15407. [Abstract]
- Insect Mol Biol. 2024 Jun;33(3):206-217. [Abstract]
- Biomed Res Int. 2021 May 14:2021:5565748. [Abstract]
- Exp Ther Med. 2018 Aug;16(2):1079-1086. [Abstract]
- Sex Med. 2025 Aug 6;13(4):qfaf059. [Abstract]
- Physiol Rep. 2026 Jan;14(2):e70737. [Abstract]
- Int Heart J. 2026;67(1):65-76. [Abstract]
- Brain Dev. 2025 Jul 1;47(4):104388. [Abstract]
- Exp Anim. 2025 Oct 30. [Abstract]
- Res Sq. 2025 Nov 12.
- bioRxiv. 2025 May 06.
- University of Jena. 2023 Dec.
- bioRxiv. 2023 Dec 4.
- bioRxiv. 2023 Nov 1.
- Research Square Preprint. 2023 May 30.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2021 Feb.
- Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641. [Abstract]
Customer Validation & Images
-
IF
-
WB
-
WB
Biological Activity
IC50: 70 μM (NOS)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.68 μM
Compound: L-NAME
|
Inhibition of human recombinant eNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
Inhibition of human recombinant eNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
|
[PMID: 21923116] |
| Sf9 | IC50 |
0.69 μM
Compound: L-NAME
|
Inhibition of human recombinant nNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
Inhibition of human recombinant nNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
|
[PMID: 21923116] |
| Sf9 | IC50 |
0.83 μM
Compound: L-NAME
|
Inhibition of human recombinant iNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
Inhibition of human recombinant iNOS expressed in Sf9 cells assessed as inhibition of conversion of [3H]-L-arginine to [3H]-L-citrulline after 45 mins by liquid scintillation counting
|
[PMID: 21923116] |
L-arginine analogues are widely used inhibitors of nitric oxide synthase (NOS) activity, with Nw-nitro-L-arginine methyl ester (L-NAME) being at the head[2]. Freshly dissolved L-NAME is a 50 fold less potent inhibitor of purified brain NOS (mean IC50= 70 μM) than L-NOARG (IC50= 1.4 μM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. HPLC analyses reveal that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley (SD) rats [7]
-
Dosage:40 mg/kg, 5 weeks
-
Administration:drinking water
-
Result:Induced hypertension with body weight loss and high blood pressure.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
L-NAME hydrochloride can be used to induce hypertension models[6].
Administration: 400 mg/kg • ip • once daily for 7 days
Administration: subcutaneous injection • 50 mg/kg/day • E7.5 to E17.5
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 51298-62-5
-
Appearance Solid
-
Molecular Weight 269.69
-
Formula C7H16ClN5O4
-
Color White to off-white
-
SMILES
N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl
-
Synonyms
NG-Nitroarginine methyl ester hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (79)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction. [Abstract]2025 May 28;10(1):167. PMID: 40425583 -
Cancer Res
Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer. [Abstract]2024 Jun 14;84(12):1963-1977. PMID: 38502865 -
J Extracell Vesicles
Extracellular vesicles derived from Akkermansia muciniphila promote placentation and mitigate preeclampsia in a mouse model. [Abstract]2023 May;12(5):e12328. PMID: 37165987 -
Adv Sci (Weinh)
Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation. [Abstract]2026 May;13(25):e15367. PMID: 41722054 -
Adv Sci (Weinh)
Thrombospondin-1 Regulates Trophoblast Necroptosis via NEDD4-Mediated Ubiquitination of TAK1 in Preeclampsia. [Abstract]2024 Jun;11(21):e2309002. PMID: 38569496 -
J Nanobiotechnology
Sparking angiogenesis by carbon monoxide-rich gold nanoparticles obtained by pulsed laser driven CO2 reduction reaction. [Abstract]2025 Aug 26;23(1):590. PMID: 40859339 -
Hum Reprod Open
Impaired PIEZO1 function drives uterine hypercontractility in adenomyosis-associated dysmenorrhea. [Abstract]2026 Feb 17;2026(2):hoag013. PMID: 41836349 -
Cardiovasc Diabetol
MAP4K4 exacerbates cardiac microvascular injury in diabetes by facilitating S-nitrosylation modification of Drp1. [Abstract]2024 May 9;23(1):164. PMID: 38724987 -
Cell Commun Signal
Histone deacetylase 3 inhibition alleviates type 2 diabetes mellitus-induced endothelial dysfunction via Nrf2. [Abstract]2021 Mar 18;19(1):35. PMID: 33736642 -
Phytomedicine
Triterpenoid saponins from Ilex pubescens promote blood circulation in blood stasis syndrome by regulating sphingolipid metabolism and the PI3K/AKT/eNOS signaling pathway. [Abstract]2022 Sep:104:154242. PMID: 35728385 -
Free Radic Biol Med
Intermedin protects peritubular capillaries by inhibiting eNOS uncoupling through AMPK/GTPCH-I/BH4 pathway and alleviate CKD following AKI. [Abstract]2025 Apr 12:S0891-5849(25)00225-4. PMID: 40228707 -
Free Radic Biol Med
TRPA1 protects against contrast-induced renal tubular injury by preserving mitochondrial dynamics via the AMPK/DRP1 pathway. [Abstract]2024 Sep 13:S0891-5849(24)00659-2. PMID: 39278575 -
Biomed Pharmacother
Nicorandil reversed homocysteine-induced coronary microvascular dysfunction via regulating PI3K/Akt/eNOS pathway. [Abstract]2020 Jul:127:110121. PMID: 32407984 -
Biomed Pharmacother
A low-salt diet with candesartan administration is associated with acute kidney injury in nephritis by increasing nitric oxide. [Abstract]2023 May:161:114484. PMID: 36921530
L-NAME hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114484. [Abstract]
L-NAME (10 mg/kg; i.p.; single daily for 7 days; pretreat) alleviates Candesartan-induced glomerular shrinkage and renal tubular necrosis and detachment, in low-salt rats.
-
Biomed Pharmacother
Antihypertensive effects of allicin on spontaneously hypertensive rats via vasorelaxation and hydrogen sulfide mechanisms. [Abstract]2020 Aug;128:110240. PMID: 32480217 -
Biomed Pharmacother
2019 Jul:115:108934. PMID: 31082773 -
Arterioscler Thromb Vasc Biol
Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling. [Abstract]2020 Jul;40(7):1705-1721. PMID: 32268790 -
Aging Cell
Vascular Endothelial NAMPT-Mediated NAD+ Biosynthesis Regulates Angiogenesis and Cardiometabolic Functions in Male Mice. [Abstract]2025 Sep 29:e70222. PMID: 41021357 -
Aging Cell
Aging-Associated Liver Sinusoidal Endothelial Cells Dysfunction Aggravates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. [Abstract]2025 Feb 6:e14502. PMID: 39912563 -
JCI Insight
2021 Sep 22;6(18):e133690. PMID: 34403364 -
Int J Mol Med
Naringenin modulates the NO‑cGMP‑PKG signaling pathway by binding to AKT to enhance osteogenic differentiation in hPDLSCs. [Abstract]2024 Aug;54(2):67. PMID: 38940332 -
Chem Biol Interact
Platycodin D reverses tumor necrosis factor-α-induced endothelial dysfunction by increasing nitric oxide through G protein-coupled estrogen receptor-mediated eNOS activity. [Abstract]2025 May 28:111577. PMID: 40447174 -
J Ethnopharmacol
Ginkgo biloba L. extract prevents steroid-induced necrosis of the femoral head by rescuing apoptosis and dysfunction in vascular endothelial cells via the PI3K/AKT/eNOS pathway. [Abstract]2022 Oct 5:296:115476. PMID: 35724747 -
Cancer Metab
Hypoxia-induced NOS1 as a therapeutic target in hypercholesterolemia-related colorectal cancer. [Abstract]2024 May 17;12(1):14. PMID: 38755702 -
Commun Biol
GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway. [Abstract]2025 Nov 25;8(1):1682. PMID: 41291036 -
Nutrients
Puerariae lobatae Radix Alleviates Pre-Eclampsia by Remodeling Gut Microbiota and Protecting the Gut and Placental Barriers. [Abstract]2022 Nov 25;14(23):5025. PMID: 36501055 -
Biol Direct
miR-155 mediated regulation of PKG1 and its implications on cell invasion, migration, and apoptosis in preeclampsia through NF-κB pathway. [Abstract]2024 Nov 26;19(1):121. PMID: 39587640 -
Int J Mol Sci
The Enzyme 15-Hydroxyprostaglandin Dehydrogenase Inhibits a Shift to the Mesenchymal Pattern of Trophoblasts and Decidual Stromal Cells Accompanied by Prostaglandin Transporter in Preeclampsia. [Abstract]2023 Mar 7;24(6):5111. PMID: 36982197 -
Int Immunopharmacol
Targeting periodontal inflammatory microenvironment to ameliorate periodontitis: A nitrogen ions implantation technique. [Abstract]2025 Dec 24:170:116055. PMID: 41448003 -
Am J Physiol Cell Physiol
2025 Oct 30. PMID: 41165539 -
Int Immunopharmacol
CTRP13 attenuates atherosclerosis by inhibiting endothelial cell ferroptosis via activating GCH1. [Abstract]2024 Nov 13;143(Pt 3):113617. PMID: 39541845 -
Int Immunopharmacol
Epigenetic modification of TWIST1 in macrophages promotes hypertension-induced atherosclerotic plaque instability. [Abstract]2024 Jan 25:127:111313. PMID: 38134595 -
Clin Epigenetics
WTAP regulates NCOA4-mediated ferroptosis via a YTHDF2-dependent mechanism in preeclampsia. [Abstract]2025 Nov 19;17(1):195. PMID: 41257944 -
J Mol Med (Berl)
Astragaloside IV inhibits the progression of hypertensive heart disease via the RXRA/PPARG/SIRT3 axis. [Abstract]2025 Dec 16;104(1):6. PMID: 41402523 -
FASEB J
Nitric Oxide Scavenging Alleviates Scar Pruritus by Inhibiting S-Nitrosylation of Transient Receptor Potential Channels and Limiting Calcium Influx. [Abstract]2025 Jul 31;39(14):e70817. PMID: 40637249 -
FASEB J
The Effect of FPR2 on the Regulation of Trophoblast Autophagy via the PI3K/AKT/mTOR Signaling Pathway in Preeclampsia. [Abstract]2025 Jun 15;39(11):e70697. PMID: 40474580 -
Microorganisms
Pasteurized Akkermansia muciniphila Ameliorates Preeclampsia in Mice by Enhancing Gut Barrier Integrity, Improving Endothelial Function, and Modulating Gut Metabolic Dysregulation. [Abstract]2024 Dec 2;12(12):2483. PMID: 39770686 -
FASEB J
Desaminotyrosine is a redox-active microbial metabolite that bolsters macrophage antimicrobial functions while attenuating IL-6 production. [Abstract]2024 Jul 31;38(14):e23844. PMID: 39046365 -
J Cell Mol Med
NEDD4L is a promoter for angiogenesis and cell proliferation in human umbilical vein endothelial cells. [Abstract]2024 Apr;28(8):1-11. PMID: 38526036 -
Bioengineered
Knockdown of forkhead box protein P1 alleviates hypoxia reoxygenation injury in H9c2 cells through regulating Pik3ip1/Akt/eNOS and ROS/mPTP pathway. [Abstract]2022 Jan;13(1):1320-1334. PMID: 35000528 -
Mediators Inflamm
Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway. [Abstract]2020 Oct 24;2020:1649453. PMID: 33162828 -
Mediators Inflamm
Andrographolide Protects against HG-Induced Inflammation, Apoptosis, Migration, and Impairment of Angiogenesis via PI3K/AKT-eNOS Signalling in HUVECs. [Abstract]2019 Oct 7;2019:6168340. PMID: 31686985 -
Hum Gene Ther
HIV Tat- conjugated Histone H3 peptides induce tumor cell death via cellular stress responses. [Abstract]2023 Jan;34(1-2):42-55. PMID: 36373826 -
Sci Rep
Gnetum montanum extract attenuates lipopolysaccharide induced acute lung inflammation through Nrf2 and heme oxygenase 1 mediated redox modulation in macrophages. [Abstract]2026 Apr 24;16(1):18995. PMID: 42031984 -
Sci Rep
2025 Oct 31;15(1):38208. PMID: 41174031 -
Front Med
Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway. [Abstract]2021 Apr 13:8:634882. PMID: 33928100 -
Toxicol Appl Pharmacol
M1 macrophage mediated increased reactive oxygen species (ROS) influence wound healing via the MAPK signaling in vitro and in vivo. [Abstract]2019 Mar 1:366:83-95. PMID: 30690042 -
Bosn J Basic Med Sci
Nitric oxide synthesis-promoting effects of valsartan in human umbilical vein endothelial cells via the Akt/adenosine monophosphate-activated protein kinase/endothelial nitric oxide synthase pathway. [Abstract]2017 May 20;17(2):132-137. PMID: 28178430
L-NAME hydrochloride purchased from MedChemExpress. Usage Cited in: Bosn J Basic Med Sci. 2017 May 20;17(2):132-137. [Abstract]
Effects of Akt/adenosine monophosphate-activated protein kinaseon CGP 48933 (VAL)-mediated endothelial nitric oxide (NO) synthase (eNOS) phosphorylation and NO production in human umbilical vein endothelial cells (HUVECs). (A) The variation of VAL (10 μM)-induced eNOS activation after HUVECs are incubated with LY294002 [LY] (10 μM), Compound C (1 μM), L-NAME (500 μM) for 3 hours. (B)The variation of VAL (10 μM)-induced nitric oxide (NO) productionafter HUVECs are incubated with LY294002 (10 μM),
-
Int J Med Sci
Deficiency of Caveolin-1 Aggravates Cardiac Infarction Injury by Disturbing the Endothelial Homeostasis. [Abstract]2025 Jan 21;22(4):920-932. PMID: 39991756 -
Mol Cell Probes
Elevated PGT promotes proliferation and inhibits cell apoptosis in preeclampsia by Erk signaling pathway. [Abstract]2023 Feb:67:101896. PMID: 36731680 -
Peptides
Apelin/APJ increased renal blood flow through endothelial BKCa channel induced p-eNOS and ET-1 in diabetic conditions. [Abstract]2024 Dec 5:183:171333. PMID: 39644975 -
Cell Tissue Res
2022 Apr;388(1):181-194. PMID: 35091806 -
Front Cardiovasc Med
Downregulation of Cullin 3 Ligase Signaling Pathways Contributes to Hypertension in Preeclampsia. [Abstract]2021 Apr 13:8:654254. PMID: 33928137 -
Microvasc Res
Gastrodin protects endothelial cells against high glucose-induced injury through up-regulation of PPARβ and alleviation of nitrative stress. [Abstract]2023 Jul:148:104531. PMID: 36963481 -
Vet Microbiol
PDZK1 upregulates nitric oxide production through the PI3K/ERK2 pathway to inhibit porcine circovirus type 2 replication. [Abstract]2022 Sep:272:109514. PMID: 35917623 -
Int J Immunopathol Pharmacol
Formononetin regulates endothelial nitric oxide synthase to protect vascular endothelium in deep vein thrombosis rats. [Abstract]2022 Jan-Dec:36:3946320221111117. PMID: 35731855 -
Clin Exp Pharmacol Physiol
Indole-3-Propionic Acid Improves Vascular Function in High-Fat Diet-Induced Obese Mice via eNOS. [Abstract]2025 Nov;52(11):e70081. PMID: 41057979 -
J Cardiovasc Transl Res
TMAO Impairs Mouse Aortic Vasodilation by Inhibiting TRPV4 Channels in Endothelial Cells. [Abstract]2024 Dec;17(6):1415-1426. PMID: 38980653 -
Placenta
Cyclosporin A alleviates trophoblast apoptosis and senescence by promoting autophagy in preeclampsia. [Abstract]2022 Jan:117:95-108. PMID: 34785431 -
Placenta
ELABELA alleviates syncytiotrophoblast hypoxia/reoxygenation injury and preeclampsia-like symptoms in mice by reducing apoptosis. [Abstract]2021 Mar:106:30-39. PMID: 33610935 -
BMC Nephrol
Sodium selenite attenuates inflammatory response and oxidative stress injury by regulating the Nrf2/ARE pathway in contrast-induced acute kidney injury in rats. [Abstract]2024 Jul 15;25(1):226. PMID: 39009991 -
PeerJ
PFI-3 induces vasorelaxation with potency to reduce extracellular calcium influx in rat mesenteric artery. [Abstract]2023 May 25:11:e15407. PMID: 37250720 -
Insect Mol Biol
A parasitoid regulates 20E synthesis and antibacterial activity of the host for development by inducing host nitric oxide production. [Abstract]2024 Jun;33(3):206-217. PMID: 38180144 -
Biomed Res Int
Gentiopicroside Produces Endothelium-Independent Vasodilation by Deactivating the PI3K/Akt/Rho-Kinase Pathway in Isolated Rat Thoracic Aorta. [Abstract]2021 May 14:2021:5565748. PMID: 34095301 -
Exp Ther Med
Effects of ginsenoside Rb1 on oxidative stress injury in rat spinal cords by regulating the eNOS/Nrf2/HO-1 signaling pathway. [Abstract]2018 Aug;16(2):1079-1086. PMID: 30116359
L-NAME hydrochloride purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2018 Aug;16(2):1079-1086. [Abstract]
Effect of L-name on the expression of eNOS, HSP90, Nrf2, Nqo1 and HO-1 in a rat model of spinal cord injury (SCI).
-
Sex Med
Hinokiflavone alleviates high-fat diet-induced erectile dysfunction via the EGFR/PI3K/Akt/eNOS signaling pathway. [Abstract]2025 Aug 6;13(4):qfaf059. PMID: 40808867 -
Physiol Rep
Glutamine enhances endothelial cell survival and vasodilation by increasing glutathione to reduce oxidative stress. [Abstract]2026 Jan;14(2):e70737. PMID: 41566950 -
Int Heart J
Exploring the Role and Mechanism of DSF in HFpEF Based on IL-1β/IL-1βR/TAK1/RIPK1 Axis-Mediated PANoptosis. [Abstract]2026;67(1):65-76. PMID: 41621910 -
Brain Dev
L-NAME improves the morphology and necrosis of skeletal muscle by activating PINK1-PARKIN mediated mitophagy in mdx mice. [Abstract]2025 Jul 1;47(4):104388. PMID: 40602311 -
Exp Anim
Integrative network pharmacology and experimental study of Qingda granule in hypertension-induced endothelial dysfunction. [Abstract]2025 Oct 30. PMID: 41161798 -
-
-
-
-
-
-
-
-
Evid Based Complement Alternat Med
Acupuncture at Gastric Back-Shu and Front-Mu Acupoints Enhances Gastric Motility via the Inhibition of the Glutamatergic System in the Hippocampus. [Abstract]2020 Mar 10;2020:3524641. PMID: 32215036
Solvent & Solubility
H2O : 100 mg/mL (370.80 mM; Need ultrasonic)
DMSO : 100 mg/mL (370.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 140 mg/mL (519.11 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40. [Content Brief]
[2]. Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20. [Content Brief]
[3]. Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973. [Content Brief]
[4]. Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8. [Content Brief]
[5]. Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36. [Content Brief]
[6]. V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3. [Content Brief]
[7]. Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5. [Content Brief]
[8]. de Alwis N, et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci Alliance. 2022 Aug 5;5(12):e202201517. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.7080 mL | 18.5398 mL | 37.0796 mL | 92.6990 mL |
| 5 mM | 0.7416 mL | 3.7080 mL | 7.4159 mL | 18.5398 mL | |
| 10 mM | 0.3708 mL | 1.8540 mL | 3.7080 mL | 9.2699 mL | |
| 15 mM | 0.2472 mL | 1.2360 mL | 2.4720 mL | 6.1799 mL | |
| 20 mM | 0.1854 mL | 0.9270 mL | 1.8540 mL | 4.6350 mL | |
| 25 mM | 0.1483 mL | 0.7416 mL | 1.4832 mL | 3.7080 mL | |
| 30 mM | 0.1236 mL | 0.6180 mL | 1.2360 mL | 3.0900 mL | |
| 40 mM | 0.0927 mL | 0.4635 mL | 0.9270 mL | 2.3175 mL | |
| 50 mM | 0.0742 mL | 0.3708 mL | 0.7416 mL | 1.8540 mL | |
| 60 mM | 0.0618 mL | 0.3090 mL | 0.6180 mL | 1.5450 mL | |
| 80 mM | 0.0463 mL | 0.2317 mL | 0.4635 mL | 1.1587 mL | |
| 100 mM | 0.0371 mL | 0.1854 mL | 0.3708 mL | 0.9270 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz